Douglas Warner, MD
EFFECTOR Therapeutics, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Douglas Warner, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:14 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04632381 · Intravenous Zotatifin in Adults With Mild or Moderate COVID-19Effector Therapeutics · completed · Corona Virus Infection · study director
- Ph2NCT04622007 · Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)Effector Therapeutics · unknown · Non-small Cell Lung Cancer · study director
- Ph1/Ph2NCT04092673 · Study of eFT226 in Subjects With Selected Advanced Solid Tumor MalignanciesEffector Therapeutics · unknown · Solid Tumor, Adult · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.